ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery
ImaginAb, Inc., announces that it has entered into an agreement to sell a pipeline of next-generation therapeutic candidates, ...
Stifel maintains buy on Carnival stock, price target at $34
Stifel analysts maintained their Buy rating on Carnival Corporation (NYSE:CCL) shares, with a steady price target of $34.00. According to InvestingPro data, 12 analysts have recently revised their ...
Hold Rating Given for Zanzalintinib Based on STELLAR-001 Trial Outcomes
Stifel Nicolaus analyst Stephen Willey has maintained their neutral stance on EXEL stock, giving a Hold rating today.Invest with Confidence: ...
Cautious Hold Rating for Edgewise Therapeutics Amid Uncertain Differentiation and Efficacy
Paul Matteis, an analyst from Stifel Nicolaus, has initiated a new Hold rating on Edgewise Therapeutics (EWTX).Invest with Confidence: Follow ...
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
Disc Medicine, Inc. (NASDAQ: IRON) (Disc), a clinical-stage biopharmaceutical company focused on the discovery, development, ...
Stifel maintains Buy on Evolus, price target steady at $25
Stifel analysts maintained a Buy rating on Evolus (NASDAQ:EOLS) with a steady price target of $25.00. The firm's positive ...